EV/EBITDA Ratio: 18.99x
Is the EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 18.99x is 81% below its 5-year average of 101.68x, near the low end of its 5-year range (17.78x–256.24x).
As of Thursday, June 25, 2026. 55.79% below its 12-month average of 42.95x.
PODD EV/EBITDA Ratio Chart
PODD Average EV/EBITDA Ratio Chart
PODD Current vs Average EV/EBITDA Ratio Chart
PODD EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
18.99x
EV/EBITDA RATIO AVG TTM
42.95x
EV/EBITDA RATIO AVG 3Y
48.11x
EV/EBITDA RATIO AVG 5Y
101.68x
EV/EBITDA RATIO AVG 10Y
132.47x
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-55.79%
CURRENT VS 3Y AVG
-60.53%
CURRENT VS 5Y AVG
-81.32%
CURRENT VS 10Y AVG
-85.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PODD Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 18.99x | 42.95x | 48.11x | 101.68x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 21.34x | 19.40x | 19.09x |
| Baxter International Inc. (BAX)vs › | $10.87B | 25.08x | 20.38x | 19.18x | 19.14x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 43.91x | 25.08x | 17.64x | 18.57x |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 13.20x | 12.40x | 13.03x | 12.52x |
| Revvity, Inc. (RVTY)vs › | $11.78B | 18.51x | 17.11x | 19.86x | 18.26x |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 12.41x | 13.02x | 20.04x | 25.59x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 17.93x | 12.14x | 60.84x | 33.07x |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | 272.54x | 109.23x | 135.08x | 135.08x |
| Solventum Corporation (SOLV)vs › | $13.09B | 6.46x | 9.88x | 10.24x | 10.24x |
EV/EBITDA vs. its own history
At 19.0, EV/EBITDA is at an extreme level (the multiple carries little signal here), sitting higher than 1% of its 9-year history.
9-year low
17.8
median
152.1
9-year high
2072.7
EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Insulet Corp. (PODD)?
- The EV/EBITDA ratio for PODD stock is 18.99x.
- Is Insulet Corp.'s EV/EBITDA ratio high or low?
- The EV/EBITDA ratio of 18.99x is 81% below its 5-year average of 101.68x, near the low end of its 5-year range (17.78x–256.24x).
- What is the TTM average EV/EBITDA ratio for Insulet Corp. (PODD)?
- The TTM average EV/EBITDA ratio for PODD stock is 42.95x.
- What is the 3Y average EV/EBITDA ratio for Insulet Corp. (PODD)?
- The 3Y average EV/EBITDA ratio for PODD stock is 48.11x.
- What is the 5Y average EV/EBITDA ratio for Insulet Corp. (PODD)?
- The 5Y average EV/EBITDA ratio for PODD stock is 101.68x.
- What is the 10Y average EV/EBITDA ratio for Insulet Corp. (PODD)?
- The 10Y average EV/EBITDA ratio for PODD stock is 132.47x.
PODD EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-24 | 18.99x |
| 2026-06-23 | 18.38x |
| 2026-06-22 | 17.78x |
| 2026-06-18 | 18.61x |
| 2026-06-17 | 18.34x |
| 2026-06-16 | 18.84x |
| 2026-06-15 | 18.90x |
| 2026-06-12 | 19.09x |
| 2026-06-11 | 19.03x |
| 2026-06-10 | 19.21x |
| 2026-06-09 | 20.30x |
| 2026-06-08 | 19.31x |
| 2026-06-05 | 19.52x |
| 2026-06-04 | 18.69x |
| 2026-06-03 | 18.31x |
| 2026-06-02 | 18.20x |
| 2026-06-01 | 18.90x |
| 2026-05-29 | 18.51x |
| 2026-05-28 | 18.23x |
| 2026-05-27 | 18.64x |
| 2026-05-26 | 19.59x |
| 2026-05-22 | 19.72x |
| 2026-05-21 | 19.97x |
| 2026-05-20 | 19.93x |
| 2026-05-19 | 19.69x |
| 2026-05-18 | 19.43x |
| 2026-05-15 | 18.82x |
| 2026-05-14 | 18.97x |
| 2026-05-13 | 18.99x |
| 2026-05-12 | 20.15x |
| 2026-05-11 | 19.64x |
| 2026-05-08 | 19.63x |
| 2026-05-07 | 20.40x |
| 2026-05-06 | 19.28x |
| 2026-05-05 | 24.34x |
| 2026-05-04 | 24.89x |
| 2026-05-01 | 25.40x |
| 2026-04-30 | 24.99x |
| 2026-04-29 | 23.28x |
| 2026-04-28 | 26.51x |
| 2026-04-27 | 27.28x |
| 2026-04-24 | 27.46x |
| 2026-04-23 | 27.83x |
| 2026-04-22 | 28.03x |
| 2026-04-21 | 27.85x |
| 2026-04-20 | 29.05x |
| 2026-04-17 | 29.46x |
| 2026-04-16 | 29.14x |
| 2026-04-15 | 29.28x |
| 2026-04-14 | 29.14x |
| 2026-04-13 | 28.62x |
| 2026-04-10 | 28.50x |
| 2026-04-09 | 28.85x |
| 2026-04-08 | 29.43x |
| 2026-04-07 | 29.28x |
| 2026-04-06 | 29.42x |
| 2026-04-02 | 29.54x |
| 2026-04-01 | 29.93x |
| 2026-03-31 | 30.32x |
| 2026-03-30 | 30.06x |
| 2026-03-27 | 30.09x |
| 2026-03-26 | 31.49x |
| 2026-03-25 | 31.19x |
| 2026-03-24 | 32.53x |
| 2026-03-23 | 32.76x |
| 2026-03-20 | 32.76x |
| 2026-03-19 | 32.98x |
| 2026-03-18 | 33.21x |
| 2026-03-17 | 33.24x |
| 2026-03-16 | 32.42x |
| 2026-03-13 | 31.73x |
| 2026-03-12 | 34.03x |
| 2026-03-11 | 34.42x |
| 2026-03-10 | 34.33x |
| 2026-03-09 | 34.64x |
| 2026-03-06 | 34.16x |
| 2026-03-05 | 34.72x |
| 2026-03-04 | 34.99x |
| 2026-03-03 | 34.84x |
| 2026-03-02 | 35.35x |
| 2026-02-27 | 35.52x |
| 2026-02-26 | 36.21x |
| 2026-02-25 | 35.73x |
| 2026-02-24 | 35.32x |
| 2026-02-23 | 35.91x |
| 2026-02-20 | 34.85x |
| 2026-02-19 | 35.87x |
| 2026-02-18 | 37.14x |
| 2026-02-17 | 39.19x |
| 2026-02-13 | 38.62x |
| 2026-02-12 | 38.32x |
| 2026-02-11 | 39.89x |
| 2026-02-10 | 40.14x |
| 2026-02-09 | 39.06x |
| 2026-02-06 | 38.49x |
| 2026-02-05 | 38.69x |
| 2026-02-04 | 39.95x |
| 2026-02-03 | 39.95x |
| 2026-02-02 | 40.80x |
| 2026-01-30 | 40.67x |
| 2026-01-29 | 40.56x |
| 2026-01-28 | 41.04x |
| 2026-01-27 | 42.09x |
| 2026-01-26 | 43.10x |
| 2026-01-23 | 43.14x |
| 2026-01-22 | 44.46x |
| 2026-01-21 | 45.23x |
| 2026-01-20 | 45.12x |
| 2026-01-16 | 45.66x |
| 2026-01-15 | 45.47x |
| 2026-01-14 | 44.91x |
| 2026-01-13 | 44.17x |
| 2026-01-12 | 44.23x |
| 2026-01-09 | 45.87x |
| 2026-01-08 | 46.48x |
| 2026-01-07 | 47.46x |
| 2026-01-06 | 46.70x |
| 2026-01-05 | 45.01x |
| 2026-01-02 | 44.91x |
| 2025-12-31 | 45.12x |
| 2025-12-30 | 45.56x |
| 2025-12-29 | 45.61x |
| 2025-12-26 | 45.81x |
| 2025-12-24 | 45.84x |
| 2025-12-23 | 45.32x |
| 2025-12-22 | 46.27x |
| 2025-12-19 | 45.96x |
| 2025-12-18 | 46.47x |
| 2025-12-17 | 45.96x |
| 2025-12-16 | 45.82x |
| 2025-12-15 | 46.26x |
| 2025-12-12 | 46.92x |
| 2025-12-11 | 46.68x |
| 2025-12-10 | 46.84x |
| 2025-12-09 | 46.68x |
| 2025-12-08 | 46.99x |
| 2025-12-05 | 48.29x |
| 2025-12-04 | 50.08x |
| 2025-12-03 | 48.77x |
| 2025-12-02 | 49.00x |
| 2025-12-01 | 49.29x |
| 2025-11-28 | 51.85x |
| 2025-11-26 | 51.79x |
| 2025-11-25 | 52.11x |
| 2025-11-24 | 53.47x |
| 2025-11-21 | 52.47x |
| 2025-11-20 | 49.61x |
| 2025-11-19 | 54.85x |
| 2025-11-18 | 52.83x |
| 2025-11-17 | 51.98x |
| 2025-11-14 | 52.71x |
| 2025-11-13 | 52.71x |
| 2025-11-12 | 53.36x |
| 2025-11-11 | 51.70x |
| 2025-11-10 | 50.78x |
| 2025-11-07 | 50.69x |
| 2025-11-06 | 51.25x |
| 2025-11-05 | 55.58x |
| 2025-11-04 | 56.59x |
| 2025-11-03 | 56.33x |
| 2025-10-31 | 55.33x |
| 2025-10-30 | 55.15x |
| 2025-10-29 | 55.88x |
| 2025-10-28 | 57.29x |
| 2025-10-27 | 57.55x |
| 2025-10-24 | 56.70x |
| 2025-10-23 | 57.14x |
| 2025-10-22 | 58.14x |
| 2025-10-21 | 58.10x |
| 2025-10-20 | 57.73x |
| 2025-10-17 | 56.30x |
| 2025-10-16 | 55.90x |
| 2025-10-15 | 55.23x |
| 2025-10-14 | 56.25x |
| 2025-10-13 | 55.60x |
| 2025-10-10 | 55.59x |
| 2025-10-09 | 56.61x |
| 2025-10-08 | 55.76x |
| 2025-10-07 | 55.41x |
| 2025-10-06 | 55.10x |
| 2025-10-03 | 54.66x |
| 2025-10-02 | 55.19x |
| 2025-10-01 | 54.11x |
| 2025-09-30 | 54.59x |
| 2025-09-29 | 54.92x |
| 2025-09-26 | 56.20x |
| 2025-09-25 | 57.16x |
| 2025-09-24 | 57.75x |
| 2025-09-23 | 57.89x |
| 2025-09-22 | 59.16x |
| 2025-09-19 | 58.42x |
| 2025-09-18 | 58.89x |
| 2025-09-17 | 56.93x |
| 2025-09-16 | 58.65x |
| 2025-09-15 | 60.06x |
| 2025-09-12 | 60.32x |
| 2025-09-11 | 59.65x |
| 2025-09-10 | 59.60x |
| 2025-09-09 | 62.23x |
| 2025-09-08 | 61.67x |
| 2025-09-05 | 61.47x |
| 2025-09-04 | 61.13x |
| 2025-09-03 | 60.62x |
| 2025-09-02 | 60.86x |
| 2025-08-29 | 59.99x |
| 2025-08-28 | 59.59x |
| 2025-08-27 | 59.03x |
| 2025-08-26 | 58.59x |
| 2025-08-25 | 58.10x |
| 2025-08-22 | 58.41x |
| 2025-08-21 | 57.90x |
| 2025-08-20 | 58.80x |
| 2025-08-19 | 57.84x |
| 2025-08-18 | 57.07x |
| 2025-08-15 | 56.76x |
| 2025-08-14 | 55.81x |
| 2025-08-13 | 54.58x |
| 2025-08-12 | 54.74x |
| 2025-08-11 | 53.91x |
| 2025-08-08 | 54.30x |
| 2025-08-07 | 53.69x |
| 2025-08-06 | 50.12x |
| 2025-08-05 | 50.77x |
| 2025-08-04 | 51.97x |
| 2025-08-01 | 51.46x |
| 2025-07-31 | 52.08x |
| 2025-07-30 | 53.83x |
| 2025-07-29 | 52.63x |
| 2025-07-28 | 52.77x |
| 2025-07-25 | 52.40x |
| 2025-07-24 | 51.76x |
| 2025-07-23 | 51.78x |
| 2025-07-22 | 51.58x |
| 2025-07-21 | 50.76x |
| 2025-07-18 | 51.34x |
| 2025-07-17 | 51.21x |
| 2025-07-16 | 52.06x |
| 2025-07-15 | 52.36x |
| 2025-07-14 | 52.72x |
| 2025-07-11 | 52.25x |
| 2025-07-10 | 53.68x |
| 2025-07-09 | 53.69x |
| 2025-07-08 | 53.52x |
| 2025-07-07 | 54.26x |
| 2025-07-03 | 54.32x |
| 2025-07-02 | 54.42x |
| 2025-07-01 | 54.14x |
| 2025-06-30 | 56.65x |
| 2025-06-27 | 56.45x |
| 2025-06-26 | 55.88x |
| 2025-06-25 | 55.24x |
| 2025-06-24 | 56.07x |
| 2025-06-23 | 55.50x |
| 2025-06-20 | 54.70x |
| 2025-06-18 | 54.45x |
| 2025-06-17 | 54.92x |
| 2025-06-16 | 55.30x |
| 2025-06-13 | 54.96x |
| 2025-06-12 | 54.78x |
| 2025-06-11 | 54.53x |
Showing the most recent 260 of 2,344 data points. The chart above shows the full history.
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy